This Week's Must Reads
Oncologists file suit challenging Part B payment reductions, May 30 letter to HHS Secretary Alex Azar alerting him to the legal action, which was filed on May 31.
One-third of IDH1-mutated AML cases have complete response to ivosidenib , Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.
Ruxolitinib add-on boosted myeloma response, Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.
Getting to MRD in ALL boosted survival, Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.
CLL gets to MRD with combo therapy, Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.
Skin side effects of therapies for hematologic cancers, Phillips et al. J Am Acad Dermatol. 2018;78:1102-9.
Monetary support affects select prescribing, Mitchell AP et al. JAMA Intern Med. 2018 Apr 9. doi: 0.1001/jamainternmed.2018.0776
Sepsis-related coagulopathy and in-hospital death risk, Lyons PG et al. Crit Care Med. 2018 May;46(5):73642.
New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.
Dapagliflozin suppresses hepcidin, boosts hematocrit, Ghanim HA et al. AACE 2018, Abstract 228.
In hemophilia A, reduced frequency prophylaxis was safe, cut costs, Feldman BM et al. Lancet Haematol. 2018 May 3. doi: 10.1016/S2352-3026(18)30048-6.
Diarrhea more severe in those with Type A blood, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.
Transfusions cut by cell salvage in abdominal myomectomy, Gingold J et al. SGS 2018 Oral poster 18.